PMID- 26847279
OWN - NLM
STAT- MEDLINE
DCOM- 20161007
LR  - 20220311
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 57
IP  - 2
DP  - 2016 Mar
TI  - The Expression of MicroRNA-155 in Plasma and Tissue Is Matched in Human Laryngeal 
      Squamous Cell Carcinoma.
PG  - 298-305
LID - 10.3349/ymj.2016.57.2.298 [doi]
AB  - PURPOSE: Tumor-associated microRNAs have been detected in cancer, though whether 
      plasma microRNA-155 (miR-155) could be a potential biomarker for laryngeal 
      squamous cell carcinoma (LSCC) prognosis is unclear. We aimed to determine how 
      miR-155 can be used to predict the clinical characteristics of patients with LSCC 
      and correctly diagnose them. MATERIALS AND METHODS: We collected tissue samples 
      and peripheral blood samples before and after treatment from 280 LSCC cases and 
      560 controls. Real-time quantitative reverse transcription PCR was employed in 
      this study to compare the relative expression of miR-155. RESULTS: A total of 280 
      LSCC patients and 560 age- and sex-matched controls were included in the study. 
      The miR-155 level was more up-regulated in LSCC tissue than in the non-tumor 
      tissues (13.6 +/- 2.4 vs. 3.1 +/- 0.80, p<0.001). Additionally, a significantly 
      higher miR-155 level in plasma samples from LSCC patients than in those of the 
      controls (8.9 +/- 1.25 vs. 1.8 +/- 0.8, p<0.001) was reported. Tissue miR-155 showed 
      an area under the curve (AUC) of 0.933, with a sensitivity of 82.6% and a 
      specificity of 89.2%. The AUC for plasma miR-155 was 0.757, with a sensitivity of 
      58.4% and a specificity of 69.5%. When early LSCC in TNM I stage was considered, 
      tissue miR-155 showed an area under the curve of 0.804, with a sensitivity of 
      85.2% and a specificity of 87.3%. CONCLUSION: The expression of tissue and plasma 
      miR-155 were significantly up-regulated in patients with LSCC. Our work will 
      serve as a basis for further investigation, preferably large-scale validation in 
      clinical trials.
FAU - Wang, Jian Ling
AU  - Wang JL
AD  - Department of Otolaryngol Head Neck Surgery, General Hospital of Tianjin Medical 
      University, Tianjin, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Otolaryngol Head Neck Surgery, General Hospital of Tianjin Medical 
      University, Tianjin, China.
FAU - Yang, Dong
AU  - Yang D
AD  - Department of Otolaryngol Head Neck Surgery, General Hospital of Tianjin Medical 
      University, Tianjin, China.
FAU - Shi, Wen Jie
AU  - Shi WJ
AD  - Department of Otolaryngol Head Neck Surgery, Tianjin First Central Hospital, 
      Tianjin, China. dr_shiwenjie@hotmail.com.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN21 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/blood/*genetics
MH  - Carcinoma, Squamous Cell/blood/diagnosis/*genetics
MH  - Case-Control Studies
MH  - Early Diagnosis
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Head and Neck Neoplasms
MH  - Humans
MH  - Laryngeal Neoplasms/blood/diagnosis/*genetics
MH  - Male
MH  - MicroRNAs/*blood
MH  - Middle Aged
MH  - Prognosis
MH  - Real-Time Polymerase Chain Reaction
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Up-Regulation
PMC - PMC4740519
OTO - NOTNLM
OT  - MiR-155
OT  - biomarker
OT  - diagnosis
OT  - laryngeal squamous cell carcinoma
EDAT- 2016/02/06 06:00
MHDA- 2016/10/08 06:00
PMCR- 2016/03/01
CRDT- 2016/02/06 06:00
PHST- 2015/01/08 00:00 [received]
PHST- 2015/03/24 00:00 [revised]
PHST- 2015/04/22 00:00 [accepted]
PHST- 2016/02/06 06:00 [entrez]
PHST- 2016/02/06 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
PHST- 2016/03/01 00:00 [pmc-release]
AID - 57.298 [pii]
AID - 10.3349/ymj.2016.57.2.298 [doi]
PST - ppublish
SO  - Yonsei Med J. 2016 Mar;57(2):298-305. doi: 10.3349/ymj.2016.57.2.298.